World Alzheimer’s Day highlights a growing crisis: early-onset Alzheimer’s disease is often overlooked, dismissed as depression or burnout, and diagnosed years too late. The number of people under 70 living with dementia has more than doubled since 1990, rising from 5.91 million to 13.14 million in 2021. When adjusted for population growth, the rate climbed 54%, from 115 cases per 100,000 to 178 per 100,000—a sharp increase that reflects both aging populations and a rise in younger cases.
This year’s observance on September 21 focuses on early diagnosis with the theme “The Earlier You Know, The More You Can Do: A Dementia Diagnosis Matters.” Cognitive decline in a 40- or 50-year-old is far more likely to be attributed to depression, sleep deprivation, or hormonal shifts than to Alzheimer’s, which affects only 6 to 10 per 100,000 in that age group. By contrast, 10,000 to 15,000 per 100,000 experience depression in their 40s and 50s, a disparity that skews medical assumptions and delays appropriate testing.
John Showalter, MD, chief operating officer at Linus Health, notes that physicians default to common diagnoses before considering rare ones. He explains that the overlap in symptoms, memory lapses, mood changes, fatigue, makes early Alzheimer’s nearly indistinguishable from depression until functional breakdowns appear. A pilot struggling with flight logistics or a manager missing deadlines may signal the disease, yet these red flags often go unnoticed until the condition progresses.
A new tool may change that trajectory. The FDA cleared PrecivityAD2, a blood test by C2N Diagnostics, in August 2026, the first approved for adults as young as 40. Measuring amyloid and p-tau217 proteins, the test improved diagnostic accuracy in primary care from 65% to 93% when used alongside clinical assessments. Showalter suggests routine cognitive baselines, akin to blood-pressure checks, could further reduce delays. Digital assessments now take just 2.5 minutes, but widespread adoption remains limited.
Diagnostic and Coverage Challenges for Early-Onset Alzheimer’s Disease
Early-onset Alzheimer’s disease is often missed in primary care because its symptoms closely resemble more common conditions like depression or sleep deprivation. Estimates suggest only about 6 to 10 cases per 100,000 people in their 40s and 50s develop the disease, while depression affects far more, between 10,000 and 15,000 per 100,000 in the same age group. This imbalance influences how doctors assess cognitive complaints, leading to delays in proper evaluation. Some research places the incidence of young-onset Alzheimer’s higher, around 41 per 100,000 for adults aged 30 to 64, though the discrepancy highlights gaps in early detection.
